Impact Of A Comprehensive Geriatric Assessment To Manage Elderly Patients With Locally Advanced Non-Small-Cell Lung Cancers: An Open Phase Ii Study Using Concurrent Cisplatin - Oral Vinorelbine And Radiotherapy (Gfpc 08-06).

•CGA select elderly locally advanced NSCLC eligible for standard therapy.•77.5% Of these selected patients received full concurrent therapy.•22.5% Experienced toxicity grade >2 (including three treatment-related deaths).•Median PFS was 15 (95%CI: 8,7–35,2) months, OS 21.8 (95%CI: 16–NR) months.•One-, 2- and 4-year survival rates were 77.5%, 45% and 34.8%.